Acceleron Pharma Inc EV/Sales
Was ist das EV/Sales von Acceleron Pharma Inc?
EV/Sales von Acceleron Pharma Inc ist 91.88
Was ist die Definition von EV/Sales?
Enterprise value to sales ratio compares a company’s total value to its sales.
ttm (trailing twelve months)
Enterprise value/sales is a valuation ratio that compares the company's enterprise value to its annual sales. It indicates the company's capacity to generate free cash flow. In general, the lower the ratio, the cheaper the company is.
EV/Sales is most often calculated as cash and cash equivalents subtracted from the sum of market capitalization and debt and divided by annual sales. Many analysts consider EV/sales to be a more accurate metric than Price/Sales as it considers both debt and equity holders in its calculation. One of the limitations of the calculation is that sales do not take into account a company's taxes or expenses.
EV/Sales von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Acceleron Pharma Inc
Was macht Acceleron Pharma Inc?
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Unternehmen mit ev/sales ähnlich Acceleron Pharma Inc
- Eaton Vance Tax-Managed Global Diversified Equity Income Fund hat EV/Sales von 90.79
- genedrive plc hat EV/Sales von 90.81
- Royce Micro-Cap Trust Inc hat EV/Sales von 91.14
- Fairfax India hat EV/Sales von 91.22
- Honda Motor hat EV/Sales von 91.24
- Novonix hat EV/Sales von 91.58
- Acceleron Pharma Inc hat EV/Sales von 91.88
- China Huarong hat EV/Sales von 91.97
- Zeotech hat EV/Sales von 92.09
- Castillo Copper hat EV/Sales von 92.20
- Carnival International hat EV/Sales von 92.27
- Imagion Biosystems hat EV/Sales von 92.51
- Syntonic hat EV/Sales von 92.53